The Copaxone News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
March 2005   
June 2005   
July 2005   
August 2005   
October 2005   
November 2005   
December 2005   
January 2006   
February 2006   
May 2006   
June 2006   
August 2006   
October 2006   
November 2006   
December 2008   
January 2013   
May 2013   
June 2013   
July 2013   
September 2013   
October 2013   
November 2013   
November 2014   
December 2014   
January 2015   
March 2015   
April 2015   
May 2015   
July 2015   
February 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
Medical Director-Rocky Mountain MS Center

Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore

This page is powered by Blogger. Isn't yours?



Teva Ruling Clears Way for Generic Version of Multiple Sclerosis Drug

Image source: UCRTODAY

The first generic version of a multiple sclerosis drug went on the market Thursday, hours after a federal appeals court again invalidated a patent for the brand-name drug, Copaxone, a major moneymaker for Teva Pharmaceutical.
The generic drug, which will be made by Sandoz and Momenta Pharmaceuticals and will be called Glatopa, was approved by the Food and Drug Administration in April but the companies held off starting sales, apparently waiting for the court to rule on the patent.

Patients and insurers hoping for big price relief from the introduction of the generic might have to wait somewhat longer, however. Novartis, which owns Sandoz, said the generic version would have a wholesale list price of more than $63,000 a year.

That is about 18 percent less than the list price of Copaxone, according to figures supplied by Novartis, but hardly cheap. Sandoz said it would offer financial support to eligible patients, something not usually made available for generics.

There could be more price relief behind the scenes, if Sandoz and Teva vie to win favorable placement from insurers by offering bigger discounts and rebates. Prices might also drop if other companies, like Mylan, win approval from the F.D.A. to sell generic versions of Copaxone.

Teva suggested it would not give up trying to block the generic medicine, saying it was “committed to pursuing all legal pathways, including seeking further appellate review.”

Teva’s American depositary receipts closed up 18 cents, at $60.33, on Thursday though the shares dropped a little after hours. Momenta’s shares rose nearly 7 percent in regular trading and more after hours.

The patent in question would have expired on Sept. 1 anyway, if it had not been invalidated.

Copaxone is one of the leading drugs used to treat multiple sclerosis. The price of the drug has climbed steadily from about $9,000 a year when it was introduced in 1996. The original version, which the generic will mimic, requires one injection a day and now has a list price of about $74,000. A newer version of Copaxone, which requires three injections a week, costs around $60,000.

Copaxone is a rare brand-name product for Teva, which is mostly known for generics. It is also Teva’s biggest product, with sales last year of $4.2 billion, accounting for 21 percent of the company’s revenue and nearly half its profit. The United States accounted for about $3.1 billion of those sales.

Teva has fought hard to delay generic competition, filing one petition after another with the F.D.A., arguing that Copaxone was too complex a substance for a generic company to copy accurately. It has also switched most patients to the new formulation that requires only three self-injections a week, rather than an injection every day. That may make it harder for the generic, which also requires a daily injection, to gain traction.

The appeals court, the Court of Appeals for the Federal Circuit, first rejected the patent claim last year. Teva appealed to the Supreme Court, which in January said the appellate court might have erred and should reconsider the case.

The appellate court on Thursday, in a 2-1 decision, again invalidated the patent, but using somewhat different reasoning.

The issue was whether the patent claim was definite enough. The claim used the term “molecular weight” without specifying which of three possible methods should be used to measure it.

Story Source: The above story is based on materials provided by NYTIMES
Note: Materials may be edited for content and length